Avacta/Daewoong’s Joint-Venture AffyXell Paves Way For Next-Generation Stem Cell Therapy
Novel Mesenchymal Stem Cells To Secrete Antibody Mimetic Affimers
A new joint venture from Avacta and Daewoong Pharmaceutical aims to use novel mesenchymal stem cells to secrete antibody mimetic "Affimers" to treat inflammatory diseases.
